<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04675944</url>
  </required_header>
  <id_info>
    <org_study_id>BIA-51058-106</org_study_id>
    <secondary_id>2017-000245-43</secondary_id>
    <nct_id>NCT04675944</nct_id>
  </id_info>
  <brief_title>Effect of BIA 5-1058 on the Steady State Pharmacokinetics of Treprostinil</brief_title>
  <official_title>An Open-Label, Three Period, Fixed Sequence Study to Assess the Effect of a Single Dose of BIA 5 1058 200 mg on the Steady State Pharmacokinetics of Treprostinil in Healthy Subjects Under Fed Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bial - Portela C S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bial - Portela C S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effect of BIA 5-1058 200 mg on the pharmacokinetic&#xD;
      (PK) of treprostinil&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was an open-label, three period, fixed sequence study in healthy male and female&#xD;
      subjects performed at a single study center.&#xD;
&#xD;
      The study comprised:&#xD;
&#xD;
        -  Screening during Days -28 to -2 (both inclusive).&#xD;
&#xD;
        -  Three treatment periods separated by a washout period of at least 10 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 28, 2018</start_date>
  <completion_date type="Actual">May 25, 2018</completion_date>
  <primary_completion_date type="Actual">May 25, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed plasma concentration - Cmax</measure>
    <time_frame>Pre-dose (Treatment Period 1, Day 1 and Treatment Period 3, Day 6) and post-dose at 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hours</time_frame>
    <description>Primary Pharmacokinetic Parameters - BIA 5 1058</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC) from time zero to the last quantifiable concentration - AUC0-t</measure>
    <time_frame>Pre-dose (Treatment Period 1, Day 1 and Treatment Period 3, Day 6) and post-dose at 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hours</time_frame>
    <description>Primary Pharmacokinetic Parameters - BIA 5 1058</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC from time zero extrapolated to infinity - AUC0-inf</measure>
    <time_frame>Pre-dose (Treatment Period 1, Day 1 and Treatment Period 3, Day 6) and post-dose at 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hours</time_frame>
    <description>Primary Pharmacokinetic Parameters - BIA 5 1058</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed plasma concentration at steady state - Cmax,ss</measure>
    <time_frame>Pre-last dose (Treatment Period 2, Day 6 and Treatment Period 3, Day 6) and post-last dose at 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hours.</time_frame>
    <description>Primary Pharmacokinetic Parameters - Treprostinil</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC over the dosing interval at steady state - AUC0-τ,ss</measure>
    <time_frame>Pre-last dose (Treatment Period 2, Day 6 and Treatment Period 3, Day 6) and post-last dose at 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hours.</time_frame>
    <description>Primary Pharmacokinetic Parameters - Treprostinil</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>BIA 5-1058 / treprostinil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three treatment periods separated by a washout period of at least 10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIA 5-1058</intervention_name>
    <description>200 mg (2 x 100 mg tablets), oral route</description>
    <arm_group_label>BIA 5-1058 / treprostinil</arm_group_label>
    <other_name>Zamicastat</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>treprostinil</intervention_name>
    <description>1 mg (1 extended-release tablet), oral route</description>
    <arm_group_label>BIA 5-1058 / treprostinil</arm_group_label>
    <other_name>Orenitram</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provided a signed and dated informed consent before any study specific procedures were&#xD;
             conducted.&#xD;
&#xD;
          2. Male and female subjects aged 18 to 45 years (both inclusive) at the Screening Visit.&#xD;
&#xD;
          3. Healthy as determined by the Principal Investigator based on medical history, physical&#xD;
             examination, clinical laboratory test results, vital signs and digital 12 lead&#xD;
             electrocardiogram (ECG). If a vital sign or ECG assessment was outside of the&#xD;
             reference range at the Screening Visit or baseline, the assessment could have been&#xD;
             repeated once as soon as possible and in any cases before enrolment to rule out any&#xD;
             error.&#xD;
&#xD;
          4. Non-smoker or ex-smoker for at least 3 months prior to the Screening Visit.&#xD;
&#xD;
          5. Body mass index (BMI) between 18.5 and 29.9 kg/m2 (both inclusive) at the Screening&#xD;
             Visit and on admission to each treatment period.&#xD;
&#xD;
          6. Negative test results for hepatitis B surface antigen (HBsAg), hepatitis B core&#xD;
             antibody (anti HBc), immunoglobulin M (IgM) anti-HBc, hepatitis C virus antibody (anti&#xD;
             HCV) and human immunodeficiency virus (HIV) (Types 1 and 2) antibodies at the&#xD;
             Screening Visit.&#xD;
&#xD;
          7. Negative screen for alcohol and drugs of abuse at the Screening Visit and on admission&#xD;
             to each treatment period.&#xD;
&#xD;
          8. Subject had to be willing and able to be confined to the clinical unit and had to&#xD;
             adhere to the study and lifestyle restrictions.&#xD;
&#xD;
          9. Contraception requirements:&#xD;
&#xD;
        Male subjects had to use together with his female partner/spouse a highly effective&#xD;
        contraception form of birth control in combination with a barrier method throughout the&#xD;
        clinical study period and agreed not to father a child or to donate sperm starting at the&#xD;
        Screening Visit and throughout the clinical study.&#xD;
&#xD;
        Female subjects had to either be of non childbearing potential or had to use highly&#xD;
        effective methods of contraception from at least 3 months before the Screening Visit and&#xD;
        throughout the clinical study in combination with a barrier method.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
        Subjects who met the following criteria were considered eligible to participate/continue in&#xD;
        the study:&#xD;
&#xD;
          1. Provided a signed and dated informed consent before any study specific procedures were&#xD;
             conducted.&#xD;
&#xD;
          2. Male and female subjects aged 18 to 45 years (both inclusive) at the Screening Visit.&#xD;
&#xD;
          3. Healthy as determined by the Principal Investigator based on medical history, physical&#xD;
             examination, clinical laboratory test results, vital signs and digital 12 lead&#xD;
             electrocardiogram (ECG). If a vital sign or ECG assessment was outside of the&#xD;
             reference range at the Screening Visit or baseline, the assessment could have been&#xD;
             repeated once as soon as possible and in any cases before enrolment to rule out any&#xD;
             error.&#xD;
&#xD;
          4. Non-smoker or ex-smoker for at least 3 months prior to the Screening Visit.&#xD;
&#xD;
          5. Body mass index (BMI) between 18.5 and 29.9 kg/m2 (both inclusive) at the Screening&#xD;
             Visit and on admission to each treatment period.&#xD;
&#xD;
          6. Negative test results for hepatitis B surface antigen (HBsAg), hepatitis B core&#xD;
             antibody (anti HBc), immunoglobulin M (IgM) anti-HBc, hepatitis C virus antibody (anti&#xD;
             HCV) and human immunodeficiency virus (HIV) (Types 1 and 2) antibodies at the&#xD;
             Screening Visit.&#xD;
&#xD;
          7. Negative screen for alcohol and drugs of abuse at the Screening Visit and on admission&#xD;
             to each treatment period.&#xD;
&#xD;
          8. Subject had to be willing and able to be confined to the clinical unit and had to&#xD;
             adhere to the study and lifestyle restrictions.&#xD;
&#xD;
          9. Contraception requirements:&#xD;
&#xD;
        Male subjects had to use together with his female partner/spouse a highly effective&#xD;
        contraception form of birth control in combination with a barrier method throughout the&#xD;
        clinical study period and agreed not to father a child or to donate sperm starting at the&#xD;
        Screening Visit and throughout the clinical study.&#xD;
&#xD;
        Female subjects had to either be of non childbearing potential or had to use highly&#xD;
        effective methods of contraception from at least 3 months before the Screening Visit and&#xD;
        throughout the clinical study in combination with a barrier method.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects that met any of the following criteria were not considered eligible to&#xD;
        participate/continue in the study:&#xD;
&#xD;
          1. Clinically relevant history or presence of respiratory, gastrointestinal, renal,&#xD;
             hepatic, hematological, lymphatic, neurological, cardiovascular, psychiatric,&#xD;
             musculoskeletal, genitourinary, immunological, dermatological, endocrine, connective&#xD;
             tissue disease or disorders within 5 years before the first investigational medicinal&#xD;
             product (IMP) administration.&#xD;
&#xD;
          2. Documented coronary artery disease (any of prior myocardial infarction, positive&#xD;
             stress test, positive nuclear perfusion study, prior coronary artery bypass graft&#xD;
             [CABG] surgery or percutaneous coronary intervention, angiogram showing at least 75%&#xD;
             stenosis in a major coronary artery), acute coronary syndrome or current symptoms of&#xD;
             myocardial ischemia and angina.&#xD;
&#xD;
          3. Clinically relevant surgical history that involved the stomach and/or intestinal&#xD;
             system, potentially affecting absorption of IMPs.&#xD;
&#xD;
          4. Any clinically relevant findings in the laboratory tests, particularly any abnormality&#xD;
             in the coagulation tests or the liver function tests, as judged by the Principal&#xD;
             Investigator, at the Screening Visit and on admission to each treatment period. If a&#xD;
             laboratory assessment was outside of the reference range at the local laboratory at&#xD;
             the Screening Visit or baseline, the assessment could have been repeated once as soon&#xD;
             as possible and in any cases before enrolment to rule out laboratory error.&#xD;
&#xD;
          5. Subjects with alanine aminotransferase (ALT) &gt; 1.0 x the upper limit of normal (ULN)&#xD;
             and/or aspartate aminotransferase (AST) &gt; 1.0 x ULN and/or total bilirubin &gt; 1.0 x ULN&#xD;
             (isolated bilirubin &gt; 1.0 x ULN and ≤ 1.5 x ULN was acceptable if bilirubin was&#xD;
             fractionated and direct bilirubin &lt; 35%), as confirmed by subsequent repeat&#xD;
             assessment, at the Screening Visit and on admission to each treatment period.&#xD;
&#xD;
          6. History of relevant atopy or drug hypersensitivity.&#xD;
&#xD;
          7. History of alcoholism or drug abuse.&#xD;
&#xD;
          8. History of drinking &gt; 24 g (males) and &gt; 12 g (females) of pure alcohol per day (10 g&#xD;
             pure alcohol = 250 mL of beer [5%] or 35 mL of spirits [35%] or 100 mL of wine [12%])&#xD;
             within 3 months before first admission to the clinical unit.&#xD;
&#xD;
          9. Use of alcohol within 72 hours before the Screening Visit and from 48 hours before&#xD;
             dosing until completion of the Follow-up Visit.&#xD;
&#xD;
         10. Significant infection or known inflammatory process at the Screening Visit or upon&#xD;
             admission to all Treatment Periods, as judged by the Principal Investigator.&#xD;
&#xD;
         11. Acute gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea, heartburn) at the&#xD;
             time of the Screening Visit or upon admission to all treatment periods.&#xD;
&#xD;
         12. Subjects with blood pressure (BP) measurements (mean of triplicate) outside the&#xD;
             ranges, at the Screening Visit or admission to the first treatment period:&#xD;
&#xD;
               -  Systolic blood pressure (SBP) &lt; 100 mmHg or &gt; 140 mmHg&#xD;
&#xD;
               -  Diastolic blood pressure (DBP) &lt; 60 mmHg or &gt; 90 mmHg&#xD;
&#xD;
         13. Symptomatic orthostatic hypotension (drop of &gt; 20 mmHg in SBP and/or &gt; 10 mmHg in DBP&#xD;
             when moving from supine to standing position), together with other symptoms, e.g.,&#xD;
             dizziness, at the Screening Visit or admission to the first treatment Period.&#xD;
&#xD;
         14. Abnormal fundoscopy.&#xD;
&#xD;
         15. Electrocardiogram (mean of triplicate) with corrected QT interval using the&#xD;
             Fridericia's formula (QTcF) &gt; 450 ms at the Screening Visit or admission to the first&#xD;
             treatment period.&#xD;
&#xD;
         16. Having an estimated glomerular filtration rate (eGFR) &lt; 90 mL/min, based on creatinine&#xD;
             clearance calculation by the Cockcroft Gault formula and normalized to an average&#xD;
             surface area of 1.73m2.&#xD;
&#xD;
         17. Previous use of BIA 5 1058.&#xD;
&#xD;
         18. Use of any investigational drug or participation in any clinical study within 60 days&#xD;
             or 5 half life times, whichever was longer, before the first administration of IMP.&#xD;
&#xD;
         19. Having received IMP in more than 3 studies within 12 months before the Screening&#xD;
             Visit.&#xD;
&#xD;
         20. Donated or received blood within 56 days before first administration of IMP.&#xD;
&#xD;
         21. Donated or received plasma within 30 days before first administration of IMP.&#xD;
&#xD;
         22. History of any significant bleeding within the last 56 days prior to first&#xD;
             administration of IMP.&#xD;
&#xD;
         23. Vegetarians, vegans or other medical dietary restrictions.&#xD;
&#xD;
         24. Not able to communicate reliably with the Principal Investigator.&#xD;
&#xD;
         25. Unlikely to comply with the requirements of the study.&#xD;
&#xD;
         26. Use of over the counter (OTC) medications (including oral natural health products,&#xD;
             vitamin, and herbal supplements) within 7 days before the first IMP administration&#xD;
             until the Follow up Visit.&#xD;
&#xD;
               -  Use of prescription medications that could have affected the safety or other&#xD;
                  study assessments, in the Principal Investigator's opinion, within 14 days before&#xD;
                  the first IMP administration until the Follow-up Visit. By exception,&#xD;
                  acetaminophen/paracetamol -1000 mg/day was permitted.&#xD;
&#xD;
               -  CYP2B6, CYP2C8, CYP2D6, CYP3A4 (BIA 5-1058 metabolism) and CYP2C9, CYP2C8&#xD;
                  (treprostinil metabolism): use of inhibitors taken within 7 days before the first&#xD;
                  IMP administration and inducers taken within 28 days before first IMP&#xD;
                  administration.&#xD;
&#xD;
         27. Any known allergy or contraindication to any of the IMPs or their content.&#xD;
&#xD;
         28. The subject was an employee or the close relative of an employee of the Sponsor or the&#xD;
             Contract Research Organization (CRO) involved in the clinical study.&#xD;
&#xD;
         29. Vulnerable subjects, e.g., subjects kept in detention, protected adults under&#xD;
             guardianship, trusteeship and soldiers or subjects committed to an institution by&#xD;
             governmental or juridical order.&#xD;
&#xD;
             If female:&#xD;
&#xD;
         30. Pregnant or breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>PAREXEL International - Early Phase Clinical Unit</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 15, 2020</study_first_submitted>
  <study_first_submitted_qc>December 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2020</study_first_posted>
  <last_update_submitted>December 15, 2020</last_update_submitted>
  <last_update_submitted_qc>December 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Arterial Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Treprostinil</mesh_term>
    <mesh_term>Zamicastat</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

